Skip to Main Content
BLACK FRIDAY SALE

60% off Quiver Premium for new subscribers

...

Use Promo Code:

BLACKFRIDAY26
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Teva shares fall as R&D leadership change and legal overhang unsettle investors

None

Teva Pharmaceutical Industries (TEVA) is down 6.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The sharp move appears tied primarily to Teva’s disclosure that its head of global R&D and chief medical officer is stepping down immediately, an unexpected leadership change that arrived just one week after the company’s R&D Day. Investors may also be weighing the company’s ongoing legal overhang after a new settlement in the multistate generic-drug price-fixing case, even though terms were not disclosed.

Details:

  • Teva filed an 8-K stating that Dr. Eric Hughes notified the company on November 17, 2026 of his intention to resign, and he stepped down immediately from his executive role.
  • The company said David Gardiner, head of innovative medicines and clinical development, will serve as transition lead for R&D until a permanent successor is named.
  • Teva said its R&D strategy and priorities remain unchanged and pointed back to the growth plan presented at its November 11, 2026 R&D Day, which targeted $6 billion to $7 billion in innovative medicines revenue by 2030.
  • This could also be because investors are reassessing legal risk after Teva reached a settlement with most U.S. states in the long-running generic-drug price-fixing litigation, while its latest quarterly filing still showed billions of dollars in legal settlement and loss contingency reserves.
  • Sources:

    SEC, Teva Pharmaceuticals, Yahoo Finance

    Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

    $TEVA Insider Trading Activity

    TEVA Insider Trades

    $TEVA insiders have traded $TEVA stock on the open market 24 times in the past 6 months. Of those trades, 0 have been purchases and 24 have been sales.

    Here’s a breakdown of recent trading of $TEVA stock by insiders over the last 6 months:

    • ROBERTO MIGNONE sold 367,600 shares for an estimated $14,356,801
    • RICHARD D FRANCIS (President and CEO) has made 0 purchases and 2 sales selling 256,153 shares for an estimated $10,770,530.
    • ELIYAHU SHARON KALIF (EVP, Chief Financial Officer) sold 106,563 shares for an estimated $3,633,308
    • MARK SABAG (See "Remarks") sold 44,710 shares for an estimated $1,973,544
    • RICHARD DANIELL (EVP, Europe Commercial) has made 0 purchases and 2 sales selling 45,003 shares for an estimated $1,928,944.
    • AMIR WEISS (Chief Accounting Officer) has made 0 purchases and 5 sales selling 26,734 shares for an estimated $1,099,350.
    • DOV BERGWERK (Interim Cheif Legal Officer) has made 0 purchases and 2 sales selling 26,260 shares for an estimated $1,095,567.
    • ERIC A HUGHES (See "Remarks") sold 25,578 shares for an estimated $892,050
    • MATTHEW SHIELDS (EVP, Global Operations) has made 0 purchases and 2 sales selling 26,184 shares for an estimated $853,876.
    • EVAN LIPPMAN (EVP, Business Development) sold 18,600 shares for an estimated $680,291
    • PLACID JOVER (See "Remarks") sold 12,827 shares for an estimated $447,350
    • BRIAN SAVAGE (Interim Chief Legal Officer) has made 0 purchases and 3 sales selling 7,342 shares for an estimated $285,215.
    • RONIT SATCHI-FAINARO sold 415 shares for an estimated $15,458
    • TAL ZVI ZAKS sold 17 shares for an estimated $592

    To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

    $TEVA Hedge Fund Activity

    We have seen 297 institutional investors add shares of $TEVA stock to their portfolio, and 441 decrease their positions in their most recent quarter.

    Here are some of the largest recent moves:

    To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

    $TEVA Analyst Ratings

    Wall Street analysts have issued reports on $TEVA in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

    Here are some recent analyst ratings:

    • Barclays issued a "Overweight" rating on 11/19/2026
    • HC Wainwright & Co. issued a "Buy" rating on 11/17/2026
    • Argus Research issued a "Buy" rating on 11/17/2026
    • Piper Sandler issued a "Overweight" rating on 11/12/2026
    • Leerink Partners issued a "Outperform" rating on 11/05/2026
    • TD Cowen issued a "Buy" rating on 11/04/2026
    • JP Morgan issued a "Overweight" rating on 10/12/2026

    To track analyst ratings and price targets for $TEVA, check out Quiver Quantitative's $TEVA forecast page.

    $TEVA Price Targets

    Multiple analysts have issued price targets for $TEVA recently. We have seen 9 analysts offer price targets for $TEVA in the last 6 months, with a median target of $50.0.

    Here are some recent targets:

    • Glen Santangelo from Barclays set a target price of $50.0 on 11/19/2026
    • Douglas Tsao from HC Wainwright & Co. set a target price of $54.0 on 11/17/2026
    • An analyst from Argus Research set a target price of $50.0 on 11/17/2026
    • David Amsellem from Piper Sandler set a target price of $56.0 on 11/12/2026
    • Daniel Clark from Leerink Partners set a target price of $52.0 on 11/05/2026
    • Joseph Thome from TD Cowen set a target price of $57.0 on 11/04/2026
    • Chris Schott from JP Morgan set a target price of $50.0 on 10/12/2026

    This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.

    Add Quiver Quantitative to your preferred sources on Google Google News Logo

    Suggested Articles